REGISTRY OF SEVERE CUTANEOUS ADVERSE REACTIONS TO DRUGS AND COLLECTION OF BIOLOGICAL SAMPLES. R e g i S C A R PATIENT'S DATA. Age country of birth

Similar documents
Skin Manifestations of Drug Reactions

Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis.

Future of Pediatrics: Blisters, Hives and Other Tales from the Emergency Room June 14 th, 2016

Cutaneous Drug Reactions

Drug Allergy A Guide to Diagnosis and Management

Emergency Dermatology Dr Melissa Barkham

Rashes Not To Be Missed In Children

New product information wording Extracts from PRAC recommendations on signals

Five things not to miss in Dermatology. Dr Judy Wismer Associate Clinical Professor Michael G DeGroote School of Medicine

Bacterial Infections in Pediatric Dermatology. Patrick McMahon, MD Children s Hospital of Philadelphia

DERMATOLOGICAL EMERGENCIES. DR. Ian Hoyle MBBS DIP IMC RCS (Ed), DA (UK),FRACGP,FACRRM,DIP DERM(Wales) TASMANIAN SKIN AND BODY CENTRE

To update the use of IVIG and CORTICOIDS IN management of SJS/ TEN To remind Doctors being careful when giving

N N N N N N N N N N N N N N N N N N N N N N N

Phototherapy and Photochemotherapy Treatment (Ultraviolet A [PUVA] and B [UBV])

A Retrospective Study of Spectrum of Nevirapine Induced Cutaneous Drug Reactions in HIV Positive Patients

Vulval dermatoses. Dr Fiona Lewis, Consultant Dermatologist St John s Institute of Dermatology, London & Heatherwood & Wexham Park Hospital, Slough

ANTIBIOTICS ACUTE RHINOSINUSITIS IN CHILDREN

Past Medical History. Chief Complaint: Patient Name: Appointment Date: Page 1

Herbal and homeopathic products, often considered natural and non-toxic, can also cause adverse drug reactions.

Dermatology GP Referral Guidelines

=ﻰﻤاﻤﺤﻠا ﺔﻴﻘﻠﺤﻠا ﺔذﺒاﻨﻠا

IMPACT #: Local Inventory #: form 04. Age at admission: d. mo yr. Postal code:

Dilantin (phenytoin) ROBERT A. SCHWARTZ

F M S M W D. Age Birth Date Gender Marital Status Cell Phone

LECOM Health Ophthalmology

HEMORRHAGIC BULLOUS HENOCH- SCHONLEIN PURPURA: A CASE REPORT

Hospital-based Dermatopathology. Janis M. Taube, MD Director of Dermatopathology Johns Hopkins University SOM

Annex I. Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation(s)

Bugs and Drugs: What s New in Hypersensitivity Reactions?

PATIENT REGISTRATION INFORMATION DENTAL INSURANCE INFORMATION. Title:! Mr.! Mrs.! Ms.! Miss! Dr. Patient: Last Name: First Name: Middle:

International IBD Genetics Consortium

Case 1. Debridement Cultures Keflex Silvadene

HEALTH SCREENING QUESTIONNAIRE CT Work-up. Donor ID EdgeCell #:

Cutanous Manifestation of Lupus Erythematosus. Presented By: Dr. Naif S. Al Shahrani Salman Bin Abdaziz university

For Office Use Only: MA complete Date of Visit / / mm/dd/yyyy. This form must be scanned into the medical record. Do not remove from clinic.

Pediatric Dermatology

2. Have your symptoms affected your ability to carry out your daily activities? YES NO

A. Erythema multiforme and related diseases

Radford University School of Nursing GRADUATE HEALTH RECORD FORM

Patient Last Name First Name Middle Name. Home Address City State Zip. Date of Birth Age Social Security # - - Cell Phone Home Phone Work Phone

We will review the need for continuing treatment with you after 3 months and again after one year.

Pharmacy Prior Authorization

PATIENT INFORMATION. Date: Patient Name: SS#: Address: City: State: Zip: Phone: (Home) (Work) (Cell)

LYMPHOMA Joginder Singh, MD Medical Oncologist, Mercy Cancer Center

Name of Recipient: Recipient s DOB (if known) Relationship to Recipient: (Example: mother, father, sister, brother, friend, etc)

The Old, The New and the Reemerging-HIV Dermatology. Toby Maurer, MD

PATIENT DEMOGRAPHIC SHEET

This page is for information. Do not submit.

Part I: Health Form. This form is to be completed by the incoming student by July 15. Name: Date of Birth:

Erythematous rash icd 10

Member's Name RECOMMENDATION

Clinical Pearls Infectious Diseases. Pritish K. Tosh, MD MN ACP Nov 7, [Answers and discussion slides will be posted after the meeting]

Crohn's disease CAUSES COURSE OF CROHN'S DISEASE TREATMENT. Sulfasalazine

Methotrexate for inflammatory bowel disease: what you need to know

Supplementary Online Content

What Are the Different Forms?

SUMMARY. Research hypotheses:

Patient Information. Spouse or Responsible Party Information. Insurance Information

Inflammatory Bowel Disease Medical Exam Questionnaire

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:

Pre-Admission Testing Questionnaire

AUTOIMMUNE DISORDERS IN THE ACUTE SETTING

Big rashes in little patients:

HEALTH SCREENING QUESTIONNAIRE. Work-up. Donor ID EdgeCell #:

PedsCases Podcast Scripts

PATIENT INFORMATION. Name: First Name MI Last Name. Date of Birth: / / Sex: Male / Female / Declined SSN:

Name. Address. City State Zip. Home Phone . Cell Phone Can we contact you by text message? Today s Date Date of Birth.

An Evidenced-Based Approach to the Adult with a Morbilliform Eruption

Dermatology Pearls for Inpatient Medicine. Dr Peter J Green MD FRCPC Professor, Division of Dermatology Dalhousie University

PATIENT INFORMATION. Last Name First Name MI. Address. City State Zip. Cell Phone _( ) Home Phone _( ) May we contact you by ?

Reducing the burden of squamous cell carcinoma in Fanconi Anemia - Initial study questionnaire -

Rayos Prior Authorization Program Summary

Influenza-Associated Pediatric Mortality Case Report Form Form Approved OMB No

NEW GYN PATIENT HISTORY FORM (OB PATIENTS, please DO NOT USE THIS FORM. Thanks.)

CPC. Chutika Srisuttiyakorn, M.D. Kobkul Aunhachoke, M.D. Phramongkutklao Hospital Bangkok, Thailand

We are an academic institution What does that mean?

Past Medical History. Chief Complaint: Appointment Date: Page 1

Past Skin History (Please check the applicable boxes to the patient s history or choose the first box)

6140 W Atlantic Avenue * Delray Beach, FL Tel: (561) * (888) 357-DERM * Fax: (561)

DERMATOLOGY AND VENEREOLOGY

The Role of Plasmacytoid Dendritic Cells in Psoriasis

Prior Authorization Conditions for Approval of Humira (adalimumab) Website Form Submit request via: Fax

Address: 1. What is your vulvar diagnosis (if known)? 2. What is the main symptom for which you are coming to the Vulvar Mucosal Specialty Clinic?

MEDICAL HISTORY DO YOU HAVE OR HAVE YOU HAD ANY OF THE FOLLOWING PLEASE CHECK ALL THAT APPLY. Patients s Name Date Yes No Yes No

Why have I been selected for treatment with adalimumab?

Clinical profile of skin diseases in accident and emergency department attenders

Improving outcome of Inflammatory Bowel Disease in children

LRI Children s Hospital. Management of chicken pox exposure in paediatrics

MEDICAL ASSESSMENT FOR DEFILEMENT

*

IN-VITRO FERTILIZATION WITH DONATED OOCYTES COMPREHENSIVE HISTORY OF RECIPIENT COUPLE (HUSBAND)

MEDICAL RECORD. Last and given name(s)... Personal Identification Number PESEL.. Residence address... Phone number..

Shingles. A Guide to Understanding Herpes Zoster. By Sarah Weis, PharmD Candidate 2012

Tuberculosis Procedure ICPr016. Table of Contents

IPC-PGN 24 Part of NTW(C)23 Infection, Prevention and Control Policy

Emergency Dermatology. Emergency Dermatology

Yes No If yes Yes No If yes Yes No If yes Yes No If yes Yes No If yes Yes No If yes. Yes No Yes No

Table of Contents. Injectable Gel with 0.3% Lidocaine

Pharmacy and Referrals Pharmacy Name, Street Address & Telephone #: Primary Care Physician s Name, Location & Telephone #:

Pre-Procedure Evaluation

Transcription:

REGISTRY OF SEVERE CUTANEOUS ADVERSE REACTIONS TO DRUGS AND COLLECTION OF BIOLOGICAL SAMPLES R e g i S C A R PATIENT'S DATA Initials of the patient date of birth Age country of birth Gender male female Death before interview no Participation agreed to by the patient registry yes cohort study (only for DRESS) genetic study

- 2 - HOSPITAL DATA Reporting hospital / department hospital no. date of admission Treating hospital / department hospital no. date of admission date of notification date of interview Transfer from one or more hospitals to the reporting / treating hospital: no yes unknown first hospital: hospital no. date of admission Retrospective assessment no yes Development of skin reaction prior to admission during inhospital stay

- 3 - DIAGNOSES AND CLINICAL COURSE Admission diagnoses 1) 2) 3) Date Clinical symptoms Fever date of onset date of normalization* highest temperature ( C) method of measurement * if cured before admission

- 4 B - FOR CASES OF AGEP ONLY SKIN SYMPTOMS Subjective symptoms Burning date of onset date of resolution* Pain Pruritus Erythema, exanthema - diffuse erythema localization of exanthema: - urticarial mainly folds - maculopapular widespread - purpura face - target lesions other: - other: - unknown unknown Maximum extent of exanthema (percentage related to the BSA) Facial edema date of onset date of resolution* * if cured before discharge / death of patient (if information of grey marked fields could not observed before discharge please try to verify information via phone call)

- 5 B - FOR CASES OF AGEP ONLY Pustules - few (< 25) - many (> 25; dozens) - unknown date of onset date of resolution* Type of pustules: - follicular - non-follicular - unknown type of pustules Localization of pustules: - mainly folds - folds spared - widespread - face - other: - unknown Blisters / epidermal sheets > 5cm date of onset date of resolution* Maximum of detachment (percentage related to the BSA) Postpustular desquamation date of onset date of resolution* * if cured before discharge / death of patient (if information of grey marked fields could not observed before discharge please try to verify information via phone call)

- 6 B FOR CASES OF AGEP ONLY MUCOSAL EROSIONS Lips date of onset date of resolution* Mouth Eyes Genital Anal Nasal LABORATORY FINDINGS - Leucocytes On admission: /?l not done Maximum: /?l date of maximum - Neutrophils On admission: /?l not done Maximum: /?l date of maximum - Eosinophils not done On admission: /?l date of maximum Maximum: /?l - Pathological renal-function highest pathological values: _ - Pathological liver-function highest pathological values: _ * if cured before discharge / death of patient

- 7 - FOR ALL CASES FURTHER INFORMATION FOR CASE VALIDATION Photographs date of first occurrence Biopsy Diagnosis by a dermatologist please specify: Further photographs / biopsies and comments: Date Notes

- 8 - SYMPTOMS / EVENTS WITHIN 1 MONTH BEFORE THE RECENT SKIN REACTION Herpes labialis or fever blisters date of onset date of normalization* Do you have recurrent herpes labialis or fever blisters? date of last eruption Herpes genitalis date of onset date of normalization* Do you have recurrent genital herpes? date of last eruption *if cured before admission

- 9 - SYMPTOMS / EVENTS WITHIN 1 MONTH BEFORE THE RECENT SKIN REACTION Infections - influenza / influenza-like illness date of onset date of normalization* Was the diagnosis confirmed by a physician? Was any diagnostic test performed? Was any medication taken for treatment? - respiratory tract infection Was the diagnosis confirmed by a physician? Was any diagnostic test performed? Was any medication taken for treatment? - urinary tract infection Was the diagnosis confirmed by a physician? Was any diagnostic test performed? Was any medication taken for treatment? - other infection 1 Was the diagnosis confirmed by a physician? Was any diagnostic test performed? Was any medication taken for treatment? - other infection 2 *if cured before admission Was the diagnosis confirmed by a physician? Was any diagnostic test performed? Was any medication taken for treatment? HIV-status HIV AIDS (current status) If yes for HIV or AIDS, most recent CD4 count per?l: *if cured before admission

- 10 - HAVE YOU HAD ANY OF THE FOLLOWING DISEASES THAT ARE STILL ACTIVE? Severe liver disorders year of event Severe kidney disorders year of event Rheumatic / collagen-vascular disease - rheumatoid polyarthritis year of event - systemic lupus erythematosus - other: Was a first-degree family member diagnosed with any rheumatic/ collagen-vascular disease? Inflammatory bowel disease - Colitis ulcerosa year of event - Crohn's disease Psoriasis year of event - Pustular psoriasis, generalized Was a first-degree family member diagnosed with psoriasis? Convulsive disorder / epilepsy year of event

- 11 - HAVE YOU BEEN DIAGNOSED WITH A MALIGNANT DISEASE/CANCER WITHIN THE LAST 2 YEARS BEFORE THE REACTION OR THAT IS STILL BEING TREATED? Malignant diseases / cancer please specify: year of event please specify: HAVE YOU HAD ANY RADIOTHERAPY RECENTLY? Have you ever had X-ray or radiotherapy? (not UV-radiation) for what indication? date of most recent therapy - lymphoma - brain tumor - other reason: HAVE YOU IN THE PAST HAD ANY TRANSPLANTATION? year of transplantation Transplantation - Stem cell - other: _ HAVE YOU IN THE PAST HAD ANY SCAR? year of event SCAR please specify:

medication sheet no. of - 12 - Interview no MEDICATION HISTORY WITHIN 1 MONTH BEFORE HOSPITALIZATION date of admission drug use Drug Indication Type of application Dose Begin of intake End of intake Frequency day month year day month year previous intake any adverse reaction please specify: Drug Indication Type of application Dose Begin of intake End of intake Frequency day month year day month year previous intake any adverse reaction please specify: Drug Indication Type of application Dose Begin of intake End of intake Frequency day month year day month year previous intake any adverse reaction please specify:

medication sheet no. of - 13 - Interview no MEDICATION HISTORY WITHIN 1 MONTH BEFORE HOSPITALIZATION date of admission drug use Drug Indication Type of application Dose Begin of intake End of intake Frequency day month year day month year previous intake any adverse reaction please specify: Drug Indication Type of application Dose Begin of intake End of intake Frequency day month year day month year previous intake any adverse reaction please specify: Drug Indication Type of application Dose Begin of intake End of intake Frequency day month year day month year previous intake any adverse reaction please specify:

medication sheet no. of - 14 - Interview no MEDICATION HISTORY WITHIN 1 MONTH BEFORE HOSPITALIZATION date of admission drug use Drug Indication Type of application Dose Begin of intake End of intake Frequency day month year day month year previous intake any adverse reaction please specify: Drug Indication Type of application Dose Begin of intake End of intake Frequency day month year day month year previous intake any adverse reaction please specify: Drug Indication Type of application Dose Begin of intake End of intake Frequency day month year day month year previous intake any adverse reaction please specify:

- 15 - Have you ever had a rash / skin reaction suspected to be an adverse reaction to a drug? Drug: Type of eruption: Drug: Type of eruption: Drug: Type of eruption: Drug: Type of eruption: Drug: Type of eruption:

- 16 - DISCHARGE SHEET Discharge diagnoses 1. 2. 3. 4. 5. Results of the present admission 1. Death 2. Discharge date of death date of discharge Mycoplasma infection within two months before admission date of diagnosis If no or yes, by which diagnostic means was the diagnosis reached: serology isolation x-ray PCR unknown

- 17 - MAIN SOURCE OF INFORMATION 1) Clinical pattern of the reaction * Were the skin lesions seen by the investigator in acute stage? If not, please provide the source (e.g., family physician, dermatologist, nurse, family member) 2) Medication history * just patient * just other source please specify: * both please specify:

- 18 - ADDITIONAL REMARKS (optional) Please use the fields below to note important additional information. Please stick to the predefined topics and avoid redundancy: Here you can specify additional information regarding ethnic origin: Here you can indicate if patient died after discharge. Please provide date of death: Death date Here you can specify any other reason why follow-up investigations (DRESS) /blood sampling (SJS/TEN) could not be done: Further relevant remarks:

- 19 - FOR CASES OF AGEP ONLY THERAPY UNIT OF TREATMENT 1. Burn unit 2. Dept. of dermatology 3. Intensive care unit 4. Pediatric department 5. Internal medicine 6. Other: Did the patient receive any systemic treatment because of the pustular disorder (only to be completed, if not stated in the discharge letter)? SYSTEMIC THERAPY (steroids, other immunomodulating agents, IVIG, antibiotics, retinoids and anti-tnf) Brand name: Dosage: Application: p.o. i.v. Brand name: Dosage: Application: p.o. i.v. Brand name: Dosage: Application: p.o. i.v. Brand name: Dosage: Application: p.o. i.v.